Eris Lifesciences

Eris Lifesciences announced that its Board of Directors has approved the acquisition of the balance 30% stake in Swiss Parenterals…

New appointments to drive growth in domestic branded formulations business

Includes portfolio of metabolics, oncology, and critical care products in India and a 10-year supply agreement with Eris

This move affects pharma companies like JB Chemicals, Eris Lifesciences, Zydus Healthcare, Cipla, Sun Pharma, Sanofi India, and…

Total transaction value of the divestment is Rs 3,660 million, inclusive of working capital conveyed as part of the deal

DRL has earlier this month divested nine dermatology brands to Eris Lifesciences for Rs 2750 million ($33.3 million*). Within a…

Eris entered the dermatology segment through the acquisition of Oaknet Healthcare for Rs 6,500 million in May 2022 and…

EBITDA at Rs 1,514 million, with 32.9 per cent EBITDA margin; PAT stood at Rs 1,194 million, with 25.9 per cent PAT margin

Revenue for Q4 FY22 grew by 10 per cent YoY to Rs 3,059 million, and for FY22 grew by 11.2 per cent YoY to Rs 13,470 million

The company's EBITDA stood at Rs 1,217 million, up 13.5 per cent YoY and PAT stood at Rs 1,008 million, up 11.8 per cent YoY